Dnajc2 Antibody

What is DNAJC2 and why is it important in biological research?

DNAJC2 (DnaJ Heat Shock Protein Family Member C2) is an epigenetic factor involved in multiple cellular functions including transcriptional regulation and ubiquitination . The protein plays crucial roles in protein folding mechanisms and chaperone activity within cells, preventing protein aggregation and maintaining cellular proteostasis . Research interest in DNAJC2 has grown significantly due to its emerging role in neurodegenerative diseases, where protein misfolding and aggregation are key pathological features . Additionally, DNAJC2 has been implicated in several cancer types, including colorectal cancer, where it appears to regulate cell proliferation through the AKT/P21 signaling pathway, making it a potential target for cancer detection and therapy .

What are the key technical specifications to consider when selecting a DNAJC2 antibody?

When selecting a DNAJC2 antibody for research applications, researchers should consider several technical parameters that will impact experimental success. Host species, clonality, epitope recognition, and validated applications are critical factors. Most commercially available DNAJC2 antibodies are rabbit polyclonal antibodies with reactivity against human and mouse proteins . The epitope recognition varies between products, with antibodies targeting different regions of the DNAJC2 protein, such as amino acids 1-140, 368-621, or C-terminal regions . These antibodies have been validated for different applications including Western blot (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), and Immunocytochemistry (ICC) . When designing experiments, it's essential to select an antibody with validated performance in your specific application and species of interest.

What is the molecular profile of the DNAJC2 protein?

DNAJC2 has a calculated molecular weight of 72 kDa, though it is often observed at 80/72 kDa in experimental settings, likely due to post-translational modifications . The protein is encoded by a gene located at 7q22-31.1, a region that has shown high copy amplification in multiple cancer types . Key database identifiers include:

This detailed molecular profile is essential for proper experimental design, especially when conducting studies requiring specific targeting of DNAJC2 isoforms or domains .

What are the optimal conditions for using DNAJC2 antibodies in Western blotting?

For Western blot applications with DNAJC2 antibodies, researchers should optimize several key parameters for successful detection. Based on manufacturer recommendations, dilutions typically range from 1:500 to 1:1000 for most DNAJC2 antibodies . The protein typically migrates at 72-80 kDa, so appropriate molecular weight markers should be included . For sample preparation, protein extraction should be performed using buffers containing protease inhibitors to prevent degradation. Standard blocking solutions (5% non-fat milk or BSA in TBST) are generally effective, with overnight primary antibody incubation at 4°C yielding optimal results. Detection systems vary based on laboratory preferences, with ECL Plus being a commonly used method as mentioned in the literature . When troubleshooting, researchers should consider optimization of antibody concentration, incubation time, washing stringency, and blocking conditions if background issues occur.

How should DNAJC2 antibodies be applied in immunohistochemistry studies?

For immunohistochemistry applications, the following methodology is recommended based on published protocols: Tissue sections should first undergo deparaffinization and antigen retrieval (if fixed samples are used). Endogenous peroxidase activity should be suppressed using H₂O₂ treatment for 5 minutes at room temperature . For blocking, a combination of 10% normal goat serum and 5% BSA in TBS for 1 hour at room temperature is effective . DNAJC2 antibodies are typically used at a 1:400 dilution with overnight incubation at 4°C . After primary antibody incubation, sections should be washed thoroughly in PBS before applying HRP-conjugated secondary antibodies (generally at 1:100 dilution) . Signal detection can be performed using standard chromogenic or fluorescent detection systems. This methodology has been successfully applied in colorectal cancer tissue studies to evaluate DNAJC2 expression levels and correlate them with clinical parameters such as tumor size .

What controls should be included when performing experiments with DNAJC2 antibodies?

A robust experimental design with appropriate controls is essential when working with DNAJC2 antibodies. Researchers should include:

• Positive controls: Cell lines or tissues known to express DNAJC2 (colorectal cancer tissues have been documented to show elevated DNAJC2 expression)

• Negative controls: Samples where primary antibody is omitted or replaced with isotype-matched non-specific IgG

• Knockdown/knockout validation: Whenever possible, include DNAJC2 knockdown or knockout samples to confirm antibody specificity

• Loading controls: For Western blot, include housekeeping proteins like β-actin, which has been used as a control in DNAJC2 studies

• Peptide competition: When available, include pre-absorption of the antibody with the immunizing peptide to validate specificity

These controls help validate experimental findings and provide confidence in the specificity and sensitivity of the antibody detection.

How can non-specific binding be minimized when using DNAJC2 antibodies?

Non-specific binding is a common challenge when working with antibodies. For DNAJC2 antibodies specifically, several strategies can minimize this issue:

• Optimize antibody concentration: Start with the manufacturer's recommended dilution (typically 1:500-1:1000 for Western blot applications) and adjust as needed to minimize background while maintaining specific signal

• Improve blocking: Use 5% BSA in TBS for blocking when high background is observed, as demonstrated in successful DNAJC2 studies

• Increase washing stringency: Add additional wash steps with TBST or increase detergent concentration slightly

• Pre-adsorption: When cross-reactivity is suspected, pre-adsorb the antibody with proteins from species showing cross-reactivity

• Use highly purified antibodies: Select DNAJC2 antibodies that have undergone affinity purification, such as those purified by antigen affinity chromatography followed by Protein A purification

These approaches have been shown to improve signal-to-noise ratios in DNAJC2 detection experiments, particularly in complex samples like tumor tissues.

How should DNAJC2 antibodies be stored to maintain optimal activity?

Proper storage is critical for maintaining antibody performance over time. For DNAJC2 antibodies, manufacturers consistently recommend storing at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can damage the antibody and reduce its performance . Most commercial DNAJC2 antibodies are provided in a buffer containing PBS (pH 7.3-7.4), glycerol (typically 40-50%), and sodium azide (0.02-0.05%) as a preservative . When working with the antibody, it should be kept on ice and returned to storage promptly. If diluted for use, the working solution should generally be prepared fresh and used within 24 hours for optimal results. Following these storage guidelines maximizes antibody shelf life and ensures consistent experimental results.

What are common pitfalls when detecting DNAJC2 in different sample types?

Researchers may encounter several challenges when detecting DNAJC2 across different experimental systems:

• Tissue samples: Variable expression levels require optimization of antibody concentration; high lipid content in some tissues can increase background

• Cell lines: Endogenous expression levels vary significantly; basal expression may be too low for detection in some cell types

• Colorectal cancer samples: While DNAJC2 is frequently upregulated in CRC tissues, heterogeneity within tumors can lead to variable staining patterns

• Brain tissue: When studying DNAJC2 in neurodegenerative contexts, high lipid content can interfere with antibody accessibility

• Subcellular localization studies: DNAJC2's dual localization in nucleus and cytoplasm may require specific fixation and permeabilization protocols

To address these challenges, preliminary titration experiments, optimization of sample preparation methods, and validation with multiple detection techniques are recommended.

How can DNAJC2 antibodies be used to investigate protein-protein interactions?

DNAJC2 antibodies can be valuable tools for studying protein-protein interactions through several methodologies:

• Co-immunoprecipitation (Co-IP): Select DNAJC2 antibodies validated for immunoprecipitation applications . Cell lysates are incubated with the antibody, followed by capture with Protein A/G beads. Interacting partners can be identified by subsequent Western blotting or mass spectrometry.

• Proximity ligation assay (PLA): This technique allows visualization of protein interactions in situ using two different primary antibodies (anti-DNAJC2 and antibody against the potential interacting protein), followed by species-specific secondary antibodies conjugated to DNA oligonucleotides.

• Chromatin immunoprecipitation (ChIP): Given DNAJC2's role in transcriptional regulation , ChIP using DNAJC2 antibodies can identify DNA regions where DNAJC2 is bound, potentially as part of protein complexes.

• Fluorescence resonance energy transfer (FRET): Using fluorescently labeled DNAJC2 antibodies alongside antibodies against potential interaction partners can reveal direct protein-protein interactions.

These approaches have been instrumental in characterizing DNAJC2's interactions within the AKT/P21 signaling pathway in colorectal cancer research .

What is the role of DNAJC2 in cancer pathways and how can antibodies help elucidate these mechanisms?

DNAJC2 has emerged as a significant player in cancer biology, particularly in colorectal cancer (CRC). Research has demonstrated that DNAJC2 is upregulated in CRC tissues compared to adjacent normal tissues, and its expression levels correlate significantly with tumor size . Mechanistically, DNAJC2 promotes cell proliferation through the activation of the AKT/P21 signaling pathway . DNAJC2 antibodies are instrumental in elucidating these pathways through:

• Expression analysis: Immunohistochemistry with DNAJC2 antibodies allows assessment of protein levels across tumor stages and correlation with clinical parameters

• Signaling pathway investigation: Western blotting with antibodies against DNAJC2, AKT, phosphorylated-AKT, and P21 enables mapping of pathway activation states

• Functional studies: In knockdown or overexpression studies, DNAJC2 antibodies confirm the efficiency of experimental manipulation

• Binding partner identification: Immunoprecipitation with DNAJC2 antibodies can reveal novel interaction partners in cancer-specific contexts

Additionally, high copy amplification of the DNAJC2 gene (located at 7q22-31.1) has been reported in multiple cancer types, including prostate cancer, glioblastoma, and gastric cancer , suggesting broader relevance beyond CRC.

How can DNAJC2 antibodies be applied in neurodegenerative disease research?

DNAJC2's role in protein folding and chaperone activity makes it particularly relevant in neurodegenerative disease research, where protein misfolding and aggregation are central pathological features . DNAJC2 antibodies can be applied in several ways to investigate its role in these contexts:

• Expression profiling: Immunohistochemistry and Western blotting to compare DNAJC2 levels in affected versus healthy brain regions

• Co-localization studies: Dual immunofluorescence with DNAJC2 antibodies and markers of protein aggregates (e.g., amyloid-β, tau, α-synuclein) to assess potential interactions

• Stress response analysis: Examining DNAJC2 expression changes in response to proteotoxic stress using in vitro models

• Therapeutic target validation: Evaluating changes in DNAJC2 expression or function following experimental treatments aimed at improving protein homeostasis

These applications can help determine whether DNAJC2 dysfunction contributes to disease pathogenesis or represents a compensatory response to protein misfolding stress, potentially revealing new therapeutic avenues.

How should researchers interpret variations in DNAJC2 detection between different antibodies?

When working with multiple DNAJC2 antibodies, researchers may observe variations in detection patterns. These differences should be systematically analyzed considering several factors:

• Epitope recognition: Different antibodies target distinct regions of DNAJC2 (e.g., N-terminal amino acids 1-140, central region 368-621, or C-terminal domains) . These regions may be differentially accessible depending on protein conformation, post-translational modifications, or protein-protein interactions.

• Antibody validation: Consider the validation methods used for each antibody. Those validated through multiple approaches (Western blot, IP, IHC) and with knockdown controls typically provide more reliable results .

• Isoform specificity: DNAJC2 may exist in multiple isoforms. Antibodies targeting different regions may detect specific isoforms or all variants.

• Protocol compatibility: Some antibodies perform optimally only in specific applications or conditions. For example, epitopes may be sensitive to certain fixation methods for IHC.

To address these variations, researchers should ideally use multiple antibodies targeting different epitopes and validate findings through complementary techniques (e.g., mRNA quantification, functional assays).

What statistical approaches are appropriate for analyzing DNAJC2 expression data in cancer studies?

• Comparative analysis: For comparing DNAJC2 expression between tumor and adjacent normal tissues, paired t-tests or Wilcoxon signed-rank tests (for non-normally distributed data) are appropriate .

• Correlation with clinical parameters: Spearman's or Pearson's correlation coefficients can assess relationships between DNAJC2 expression and continuous variables like tumor size .

• Survival analysis: Kaplan-Meier curves with log-rank tests can evaluate associations between DNAJC2 expression levels and patient outcomes.

• Multivariate analysis: Cox proportional hazards models should include DNAJC2 alongside established prognostic factors to determine independent prognostic value.

• Pathway analysis: When examining DNAJC2's relationship with AKT/P21 signaling, multiple regression or structural equation modeling can help establish causality and interaction effects .

Sample size calculations should consider the typically heterogeneous nature of tumor samples, with power analyses conducted to ensure sufficient detection sensitivity for expected effect sizes.

How can researchers design experiments to investigate the regulation of DNAJC2 by miRNAs?

The regulation of DNAJC2 by microRNAs, such as miR-627-3p in colorectal cancer , represents an important research area. A comprehensive experimental design to investigate such regulation should include:

• Bioinformatic prediction: Utilize algorithms (TargetScan, miRanda, etc.) to identify potential miRNA binding sites in the DNAJC2 3'UTR.

• Expression correlation analysis: Quantify both DNAJC2 protein (using validated antibodies) and candidate miRNAs across tissue samples to identify inverse correlations .

• Direct interaction validation:

  • Luciferase reporter assays with wild-type and mutated DNAJC2 3'UTR constructs

  • miRNA mimic and inhibitor transfections followed by DNAJC2 protein quantification by Western blot

• Functional consequence assessment:

  • Cell proliferation assays (CCK-8, EdU incorporation)

  • Cell cycle analysis by flow cytometry

  • Colony formation assays

  • AKT/P21 pathway component analysis by Western blot

• Rescue experiments: Co-transfection of miRNA mimics with DNAJC2 expression constructs lacking the 3'UTR to confirm specificity

This comprehensive approach can establish both the direct regulatory relationship and its functional significance in cancer cell biology.

What emerging technologies might enhance DNAJC2 antibody applications in research?

Several cutting-edge technologies promise to expand the utility of DNAJC2 antibodies in research settings:

• Single-cell proteomics: Integration of DNAJC2 antibodies into mass cytometry (CyTOF) or single-cell Western blotting platforms could reveal cell-to-cell variability in DNAJC2 expression within heterogeneous tissues.

• Super-resolution microscopy: Techniques like STORM or PALM, when combined with highly specific DNAJC2 antibodies, could reveal previously undetectable subcellular localization patterns and co-localization with binding partners at the nanoscale level.

• Proximity labeling: Antibody-guided enzymatic tagging approaches (APEX, BioID) could identify the proximal proteome of DNAJC2 in different cellular contexts, revealing context-specific interaction networks.

• Antibody engineering: Development of recombinant DNAJC2 antibody fragments with enhanced tissue penetration or multiplexing capabilities could improve detection in complex samples.

• In vivo imaging: Near-infrared fluorophore-conjugated DNAJC2 antibodies could enable non-invasive monitoring of protein expression in animal models of cancer or neurodegeneration.

These technologies could substantially advance our understanding of DNAJC2's dynamic roles in both normal physiology and disease states.

How might DNAJC2 antibodies contribute to therapeutic development?

While current DNAJC2 antibodies are primarily research tools , their applications may extend to therapeutic development through several avenues:

• Target validation: DNAJC2 antibodies are instrumental in confirming the protein's involvement in disease mechanisms, particularly in colorectal cancer where DNAJC2 promotes cell proliferation through AKT/P21 signaling .

• Biomarker development: Given the correlation between DNAJC2 expression and tumor size in CRC , antibody-based assays could be developed for diagnostic or prognostic applications.

• Screening platforms: High-throughput immunoassays using DNAJC2 antibodies could screen compound libraries for molecules that modulate DNAJC2 expression or function.

• Antibody-drug conjugates: While current research applications use unconjugated antibodies , the specificity of DNAJC2 antibodies could potentially be harnessed for targeted drug delivery in tumors with DNAJC2 overexpression.

• Functional blocking antibodies: Development of antibodies that specifically inhibit DNAJC2's interaction with critical signaling partners could represent a novel therapeutic approach.

These applications highlight how research-grade antibodies can bridge fundamental science with translational medicine, potentially leading to new therapeutic strategies for DNAJC2-associated pathologies.

What are the key unanswered questions about DNAJC2 that antibody-based research could address?

Several critical knowledge gaps regarding DNAJC2 biology could be addressed through strategic application of antibody-based approaches:

• Tissue-specific functions: How does DNAJC2 function differ across tissue types, and are there tissue-specific isoforms or post-translational modifications that could be detected with epitope-specific antibodies?

• Stress response dynamics: How does DNAJC2 expression, localization, and interaction network change during cellular stress responses, particularly in neurodegenerative disease contexts ?

• Cancer type specificity: While DNAJC2's role in colorectal cancer has been investigated , how does its function compare across different cancer types where its gene shows amplification?

• Regulatory mechanisms: Beyond miR-627-3p , what other transcriptional, post-transcriptional, and post-translational mechanisms regulate DNAJC2 expression and activity?

• Therapeutic targeting: Which functional domains or interactions of DNAJC2 represent the most promising targets for therapeutic intervention?